Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People (MOWRI)

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Obesity and Cardiovascular Risk, Insulin Resistance, Obesity (Body Mass Index >30 kg/m2)

In brief

Obesity is a chronic disease of global public health concern, contributing to cardiovascular disease, type 2 diabetes and certain cancers. Currently approved anti-obesity drugs and surgery are expensive and not readily available in Nigeria. Metformin, approved for type 2 diabetes, has been shown to promote weight loss among obese patients in high income countries. However, metformin's effects have not yet been demonstrated in Black African populations, which may have different genetic and environmental predispositions to obesity and to the effect of metformin. This blinded, placebo-controlled, randomized trial is determining the effect of metformin on weight loss, cardiovascular disease risk and insulin resistance in Black Nigerians.

Key facts

Study ID

NCT07297290

Run by

University Of Nigeria Teaching Hospital

People needed

220

Starts

2025-07-23

Expected to finish

2027-09-30

Last updated by the study team

2025-12-22

Who can join

Age: 20 and older, up to 59. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• • Obesity (defined as body mass index ≥ 30kg/m2),
• Fasting plasma glucose (<7.0mmol/L)
• No medical treatment for weight control in the previous 12 months
• No participation in a current clinical trial

You may not qualify if…

• • Obesity (defined as body mass index ≥ 30kg/m2),
• Fasting plasma glucose (<7.0mmol/L)
• No medical treatment for weight control in the previous 12 months
• No participation in a current clinical trial

Where it is running

• Pathology Facility — Enugu, Enugu State, Nigeria (enrolling)
• University of Nigeria Teaching Hospital — Enugu, Enugu State, Nigeria (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.